Christi Shaw, Eli Lilly's president of biomedicines, will step down from her role in August, the drugmaker announced July 11.
Ms. Shaw, who assumed her role in 2017, will be replaced by the drugmaker's top executive in Japan, Patrik Jonsson.
The chief of biomedicines role is critical because many of Eli Lilly's main growth drivers fall under the biomedicine category, including its cancer and migraine prevention drugs.
Eli Lilly also announced its general counsel, Mike Harrington, will retire at the end of the year. The drugmaker is searching for his successor.